SchragLab

Today, the New England Journal of Medicine published what may be a landmark moment: doctors used customized gene editing inside a living baby to treat a deadly genetic disease called carbamoyl-phosphate synthetase 1 (CPS1) deficiency. Is it time to prepare for a world where we don’t just treat genetic diseases, we rewrite their story? Will gene editing change the future of medicine? Key Points for the Public: - Think of it as the first real-life genetic fire rescue; editing a baby’s DNA to prevent brain damage and death. - They used a tool called base editing, that is considered a precise cousin of CRISPR. - The authors corrected a disease-causing mutation in the liver using lipid nanoparticles. - You may recognize lipid nanoparticles as the same delivery technology used in mRNA COVID vaccines. - Their treatment was "tailor-made for a single patient." - The personalized gene-editing drug called k-abe was made in under 6 months (incredible!). - The single infant they used it on had a rare and fatal genetic disorder. - So far, the treatment has been safe and effective though followup has not been very long. - The infant tolerated more protein, required fewer medications, and recovered from infections without ammonia spikes (known to be bad for the brain). My take: This isn’t science fiction anymore, gene editing can be performed in real-time. Gene editing is moving beyond sickle cell. Lipid nanoparticle delivery facilitates re-dosing, making it safer and more flexible. What does this mean for the future? Neurogenetic diseases could be next in line? Could we start moving into rare brain conditions in children or even adult-onset disorders like Huntington’s or inherited forms of Parkinson’s? What was cool about this study was moving from diagnosis to therapy, in just months. The platforms like this one seem to be scalable. Many diseases could share delivery systems with only the guiding RNA changing. Ethics and oversight will be critical. Safety, long-term monitoring, and clear boundaries (e.g., no germline edits) must be built into the future of this therapy. Could this change the arc of progression for many diseases? We hope this technology and approach will move from lethal newborn disorders to slowly progressive neurologic conditions. Has gene editing moved past the dream stage? Is it time to prepare for a world where we don’t just treat genetic diseases, we rewrite their story? nejm.org/doi/full/10.1056/NE… #GeneEditing #CRISPR #Neurology #RareDisease #BaseEditing #PrecisionMedicine #NEJM #Parkinsons #Neurogenetics @ParkinsonDotOrg @FixelInstitute